<DOC>
	<DOC>NCT03078582</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.</brief_summary>
	<brief_title>Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Diagnosis of PNH by flow cytometry For treatment naive patients: subjects must not have received treatment with eculizumab prior to or during the Screening Period and must have a lactate dehydrogenase (LDH) level â‰¥2 times the upper limit of normal (xULN) during Screening For patients who previously received eculizumab: subjects must have received treatment with eculizumab for at least 6 months prior to Screening History of meningococcal disease Current systemic infection or suspicion of active bacterial infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>